Alcon Aandeel

Alcon Vorderingen

De Debiteuren van Alcon (ALC.SW) per 5 aug 2026 bedraagt 1,94 Miljard USD. In het voorgaande jaar bedroeg Debiteuren 1,74 Miljard USD — een verandering van 11,87% (hoger).

Vorderingen

1,94 MiljardUSD

YoY

11,87%

Laatst bijgewerkt:

Debiteuren van Alcon is 2026 1,94 Miljard USD. Debiteuren van Alcon was 2025 1,74 Miljard USD. Het is daarmee 11,87% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

Alcon Aandelenanalyse

Wat doet Alcon? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel Alcon

Debiteuren van Alcon bedraagt 1,94 Miljard USD in 2026.

Debiteuren van Alcon is veranderd van 1,74 Miljard USD naar 1,94 Miljard USD, wat een verandering van 11,87% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Debiteuren Alcon sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

Vorderingen vertegenwoordigen geld dat klanten aan het bedrijf verschuldigd zijn voor geleverde goederen of diensten.

USD van Debiteuren is een belangrijke factor voor beleggers. Veranderingen in deze maatstaf kunnen sterke signalen geven voor toekomstige koersontwikkelingen.

Access this data via the Eulerpool API

Balans — Alcon

Alle kengetallen — Alcon